Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business
In part 2 of our Q&A, Okamura addresses the need for biopharma companies to leverage digital technologies in disease management.
MedCity Pivot: A Conversation About Wearable Robots with Scott Davis
Scott Davis is the CEO of Ekso Bionics, an innovative medical device company making wearable exoskeletons for use in construction but perhaps, more importantly, to help people contending with spinal cord injury.
The Impact Brands: Empowering Wellness Through Natural and Holistic Solutions
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Technology Contributes to Clinician Burnout. Here’s How It Can Make It Better.
The next wave of Medtech innovation must deliver truly smart connected care—not only building on our progress in collecting and integrating information about a patient, such as vital signs, diagnostic results and health history—but also using software to prioritize this information, streamline care delivery and provide actionable insights.
Invitae’s First of Its Kind Cancer Test Receives FDA Marketing Authorization
The FDA awarded marketing authorization for a new Invitae test that uses next-generation sequencing to assess multiple genes to identify variants indicating a person’s predisposition for certain cancers. The regulatory action creates a new regulatory classification making Invitae’s test the predicate device for future cancer tests.
Newly Public Allurion Aims to Show How Med Tech Can Complement Obesity Drugs
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.
Unlocking Transparency in PBM Pricing
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Rigorous Data Are Key to Convince Payers, Investors in the World of Digital Therapeutics
Pear Therapeutics was once regarded as a digital therapeutics pioneer, but its spiral into bankruptcy has the industry searching for the best path forward. While some favor going direct to consumers, others say the solution is in generating more robust clinical trial data to persuade hesitant payers.
FDA Authorizes Better Therapeutics Mobile App for Treating Type 2 Diabetes
Better Therapeutics prescription digital therapeutic, AspyreRx, received De Novo FDA authorization for type 2 diabetes. The mobile app digitizes and personalizes cognitive behavioral therapy.
How Medicare Coverage Diversifies Access to Innovation
Appropriate Medicare reimbursement of high-intensity focused ultrasound for prostate disease is a significant development for the treatment for men 65 years and older today.
Here’s a Preview of the Startups Pitching in the Medical Device Track at MedCity INVEST
Finalists for the medical device track include an innovative, waterproof alterative to casts, a device geared to trauma care, an approach to improve early detection of lung cancer, cardiac monitoring medtech, and more. Register for the conference today!
At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
Pear Therapeutics’ Cuts Are Not Enough; ‘Strategic Alternatives’ Among Next Steps
Pear Therapeutics isn’t meeting the commercialization goals for its prescription digital therapeutics, so it’s now seeking strategic alternatives for the business. Prospective buyers can pick up Pear’s FDA-cleared products for substance use disorder, opioid use disorder, and insomnia.
Weight Loss in a Pill Device Firm Allurion Heads to NYSE via SPAC Merger
Allurion Technologies has developed a gastric balloon that does not require surgery. The merger deal taking Allurion public comes as the company continues global commercialization of its technology.
Apply to MedCity INVEST Pitch Perfect Where Investment Trends and Innovation Converge
In the runup to INVEST and the startup pitch contest, we highlight trends in investment and innovation across bipharma, diagnostics, medical devices, health tech: payer/provider, and health tech: consumer/employer. The deadline has been extended until February 28 and finalists will be announced March 31. Apply today!
Time Is Running Out to Apply for MedCity’s Largest Pitch Contest of the Year
With five tracks of startups across healthcare and life sciences, INVEST Pitch Perfect, scheduled for May 22-24 at the Ritz Carlton in Chicago, is MedCity's largest startup pitch contest of the year.
Why Digital Health Collaborations Are the Future of Medtech
Executives from Huma, Abbott, Smith & Nephew and AliveCor share how they are using real world evidence collection to support remote patient monitoring, maximize patient engagement and navigate the regulatory landscape.